Today’s AI Top Pick: CSV

9/16/2026 · Low Float Bullish Consensus Deep Rotation screen · a free sample of K3vl4r’s AI-curated picks.

AI-ranked from a screened shortlist, with entry strategy, targets, and risks.

View the live CSV price forecast →

Today's pick · Low Float Bullish Consensus Deep RotationCSVBUY NOW8.6 / 109/16/2026

Carriage Services (CSV) is the cleanest setup in the pool: it hits every checkbox with none of the red flags the other names carry. Fundamentally it's a real business — PE 11.55, fwdPe 8.87, PEG 1.22, ROE 17.13%, profit margin 10.57%, operating margin 23.38%, sales growth 1.33% — priced like a value stock with defensive funeral-services cash flow. Analyst consensus recom is 1.2 (essentially strong buy) with targetUpsidePct of 60.5%. This is the highest fundamental_score (6.75) among tickers that also show clean tape agreement, and it's the highest overall composite score (14.25). The tape confirms. All three available timeframes point the same direction: 4h forecasts +33.2/+35.12/+24.29, 1d +19.3/+35.19/+30.71, 1wk +4.92/+15.36/+21.33. bullish_prob = 1 and near_term_bullish = 1. Critically, price is not extended — pos_in_21bar_range is 0.44/4.18/0.00 across the three TFs, RSI 34.94, dd_from_21bar_high -17% to -34%. You're buying deep in the range, not chasing a breakout. Contrast this with MORN (pos 95.5 on 4h, bullish_prob 0.2), AZO (UBS Q4 miss call the day before), or RH (bigger forecasts but recom only 2.57 and debtEq 34.14). News check is clean. The only headlines are generic StockStory/Yahoo screens tagging it as a small-cap 'risky' name — no guidance cut, no dilution, no lawsuit, no short report. That is a very different profile than GPI (just priced $1.25B in senior notes — leverage event), GRCE (filed a 4.76M-share resale prospectus — overhang), AZO (UBS explicitly flagged Q4 comps miss), or KAI (CEO succession + shares trading lower). CSV also carries only 4.06% short float, so this isn't a squeeze thesis that can unwind on you. Why today, not next week: CSV is sitting essentially at the bottom of its 21-bar range on both 1d and 1wk (0.00 and 4.18 position) with RSI in the mid-30s. Waiting for confirmation means paying up into the 19–35% forecast move. The asymmetry is right here — small drawdown risk to the recent lows, forecast paths to $38–$42 on 1d/4h and $39+ on 1wk consensus.

CSV forecast chart
Entry zone
$31.80–$32.50 (scale in at current $32.28; add on any dip toward $31)
Stop loss
$29.20 (below the 21-bar low, ~9.5% risk)
First target
$36.50 (fills 1d fc_short_pct ~+13% and prior consolidation)
Longer target
$42–$44 (aligns with 1d fc_mid +35% and analyst target upside path)
Risks
  • DebtEq is elevated at 1.97 — rising rates or a credit hiccup weighs on funeral-services roll-ups
  • Small-cap illiquidity: $513M market cap, YTD -23.69% and 1yr -24.39% show the tape has been unfriendly and can gap
  • 1wk fc_short is only +4.92% — near-term weekly momentum is more muted than 4h/1d suggest; a slow grind is possible before the mid/long move
  • Sales growth only +1.33% YoY — thesis relies on multiple expansion + margin, not top-line breakout
  • Broad small-cap risk-off tape (multiple 'risky small caps' headlines this week) could keep the Russell 2000 cohort pressured
Honorable mentions
RHLargest forecast magnitudes in the pool (1wk fc_long +147%, 1d fc_long +53.7%), RSI 26.91 deeply oversold, bullish_prob 1, pos_in_range 1–3%. Held back by recom 2.57 (not strong buy), debtEq 34.14, and a fresh SeekingAlpha sell note — great trade if it works but not the cleanest fundamental story.
KAIOnly name with 4-timeframe alignment (1h/4h/1d/1wk), all positive short/mid forecasts (+8 to +19% mid-horizon), RSI 24.14 oversold, pos_in_range 0.28–6.5% on the higher TFs. CEO succession headline and 'shares trading lower' plus PE 28.58 keep it behind CSV on value + narrative.
Full ranking (15)
#SymbolVerdictScoreRead
1CSVBUY NOW8.6Cheap value stock with recom 1.2, RSI 34.94, all TFs bullish, price at bottom of range, no bad news.
2RHBUY NOW7.6Deeply oversold (RSI 26.91) with huge forecast magnitudes and 31.5% short float — coiled spring, but leverage and mixed recom cap conviction.
3KAIBUY NOW7.3Cleanest 4-TF alignment in the pool at RSI 24.14 and near-lows; CEO change is a mild overhang.
4XTLBBUY PULLBACK5.9Micro-cap biotech with all-TF positive forecasts (+20/+119/+154% weekly), no fundamentals to anchor — speculative but signal is clean.
5NXTCWAIT5.31wk forecasts strong (+80% long) but near_term_bullish only 0.2 and 4h data missing.
6SERWAIT5.1BTIG buy reit + $8 PT is nice, but 4h forecasts are negative and price already ran +29% on 1wk.
7CDNLWAIT5.0Only 1 TF available, bullish_prob null, mid-horizon forecast -15% — screen fit without tape confirmation.
8AZOAVOID4.7UBS flagged Q4 comps miss the day before — forecasts are already modest (fc_short +0.17% on 1h), don't fight a fresh negative call.
9GPIWAIT4.6Just priced $1.25B senior notes — leverage event with only marginal 1wk forecast (+6%).
10MMAWAIT4.31wk forecast negative (-6.8% long) despite 1d/4h spikes — inconsistent MTF and $10M float.
11GRCEAVOID4.2Filed 4.76M-share resale prospectus late August — dilution/overhang undercuts the 47% 4h forecast.
12MORNAVOID4.0bullish_prob 0.2, sitting at 95.5% of 4h range with negative short-horizon forecasts — chasing.
13DRMAAVOID3.81wk forecast of +15,438% is a broken data point, not a signal; $4.5M cap is a lottery ticket.
14AKTXAVOID3.51wk forecast of -100% across all horizons is a hard model reject — do not touch.
15CNCKAVOID3.4near_term_bullish 0, price at 0% of 21-bar range on 4h/1d — momentum is broken.

Get AI top picks & forecasts on any stock

K3vl4r screens the market daily and ranks the best setups with AI — forecasts, scored fundamentals & technicals, and multi-horizon price targets. Create a free account to explore them all.

Create your free account →

Already a member? Sign in · Join our Discord

⚠️ This AI-generated analysis is for informational purposes only and is not financial advice. Forecasts and scores are model outputs that can be wrong; markets involve substantial risk of loss. Do your own research.